TY - JOUR
T1 - Hypertension and insulin resistance
T2 - Role of peroxisome proliferator- activated receptor γ
AU - Itoh, Hiroshi
AU - Kentaro, Doi
AU - Tanaka, Tokuji
AU - Fukunaga, Yasutomo
AU - Hosoda, Kiminori
AU - Inoue, Gen
AU - Nishimura, Haruhiko
AU - Yoshimasa, Yasunao
AU - Yamori, Yukio
AU - Nakao, Kazuwa
PY - 1999/7/14
Y1 - 1999/7/14
N2 - 1. Insulin resistance has been highlighted as a common causal factor for hypertension, hyperlipidaemia, diabetes mellitus and obesity, all of which are recognized to occur simultaneously, and a distinct clinical entity is defined as 'multiple risk factor syndrome'. 2. Recently, a new class of antidiabetic agents, thiazolidinediones (TZD) has been developed and has been shown to improve insulin resistance by binding and activating a nuclear receptor, peroxisome proliferator-activated receptor (PPAR)γ. 3. cDNA of rat PPARγ1 and γ2 were cloned and gene regulation of PPARγ in rat mature adipocytes was examined. Hydrogen peroxide, an oxygen radical, which is recognized to be the common intracellular signal for multiple risk factors, potently down-regulated PPARγ mRNA expression in rat mature adipocytes. 4. Tumour necrosis factor (TNF)-α, which is considered to play a role in obesity-induced non-insulin-dependent diabetes mellitus and to augment oxidative stress, also suppressed PPARγ expression. 5. Thiazolidinediones dose-dependently recovered TNF-α-induced down-regulation of PPARγ mRNA expression. 6. The modulation of PPARγ expression by TZD can be one mechanism for the improvement of insulin resistance by TZD. 7. Vascular tone and remodelling are controlled by several vasoactive autocrine/paracrine factors produced by endothelial cells in response to several vascular injury stimuli, including hypertension. The PPARγ gene transcript was detected in cultured endothelial cells. 8. The administration of TZD stimulated the endothelial secretion of type-C natriuretic peptide, which is one of the natriuretic peptide family and is demonstrated by us to act as a novel endothelium-derived relaxing peptide. 9. Concomitantly, TZD significantly suppressed the secretion of endothelin, a potent endothelium-derived vasoconstricting peptide. 10. Thiazolidinediones can affect vascular tone and growth by modulating the production of endothelium-derived vasoactive substances to influence occurrence and progression of hypertension and atherosclerosis.
AB - 1. Insulin resistance has been highlighted as a common causal factor for hypertension, hyperlipidaemia, diabetes mellitus and obesity, all of which are recognized to occur simultaneously, and a distinct clinical entity is defined as 'multiple risk factor syndrome'. 2. Recently, a new class of antidiabetic agents, thiazolidinediones (TZD) has been developed and has been shown to improve insulin resistance by binding and activating a nuclear receptor, peroxisome proliferator-activated receptor (PPAR)γ. 3. cDNA of rat PPARγ1 and γ2 were cloned and gene regulation of PPARγ in rat mature adipocytes was examined. Hydrogen peroxide, an oxygen radical, which is recognized to be the common intracellular signal for multiple risk factors, potently down-regulated PPARγ mRNA expression in rat mature adipocytes. 4. Tumour necrosis factor (TNF)-α, which is considered to play a role in obesity-induced non-insulin-dependent diabetes mellitus and to augment oxidative stress, also suppressed PPARγ expression. 5. Thiazolidinediones dose-dependently recovered TNF-α-induced down-regulation of PPARγ mRNA expression. 6. The modulation of PPARγ expression by TZD can be one mechanism for the improvement of insulin resistance by TZD. 7. Vascular tone and remodelling are controlled by several vasoactive autocrine/paracrine factors produced by endothelial cells in response to several vascular injury stimuli, including hypertension. The PPARγ gene transcript was detected in cultured endothelial cells. 8. The administration of TZD stimulated the endothelial secretion of type-C natriuretic peptide, which is one of the natriuretic peptide family and is demonstrated by us to act as a novel endothelium-derived relaxing peptide. 9. Concomitantly, TZD significantly suppressed the secretion of endothelin, a potent endothelium-derived vasoconstricting peptide. 10. Thiazolidinediones can affect vascular tone and growth by modulating the production of endothelium-derived vasoactive substances to influence occurrence and progression of hypertension and atherosclerosis.
KW - Adipocytes
KW - Endothelial cells
KW - Endothelin
KW - Insulin resistance
KW - Natriuretic peptides
KW - Oxidative stress
KW - Peroxisome proliferator-activated receptor γ
KW - Risk factor
KW - Syndrome X
KW - Thiazolidinediones
UR - http://www.scopus.com/inward/record.url?scp=0032993595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032993595&partnerID=8YFLogxK
U2 - 10.1046/j.1440-1681.1999.03082.x
DO - 10.1046/j.1440-1681.1999.03082.x
M3 - Article
C2 - 10405788
AN - SCOPUS:0032993595
SN - 0305-1870
VL - 26
SP - 558
EP - 560
JO - Clinical and Experimental Pharmacology and Physiology
JF - Clinical and Experimental Pharmacology and Physiology
IS - 7
ER -